Navigation Links
Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
Date:10/10/2007

DEERFIELD, Ill., Oct. 10 /PRNewswire/ -- Astellas Pharma US, Inc. today announced that the investigational agent vernakalant hydrochloride increased conversion to normal heart rhythm (sinus rhythm, or SR) in patients with atrial fibrillation (AF) treated within 48 hours of the onset of symptoms. AF is a serious condition characterized by an irregular heart rhythm and a high heart rate, and frequently leads to emergency department visits. The study results were presented during the annual meeting of the American College of Emergency Physicians in Seattle.

"Most patients who develop symptoms of AF come to the emergency department within the first 48 hours," said Ian Stiell, MD of the University of Ottawa, Canada. "This analysis shows that vernakalant may provide emergency medicine physicians with an effective treatment option for managing acute AF."

AF is the most common cardiac arrhythmia, which leads to approximately 15 percent of all strokes.(1) The number of AF patients is expected to triple over the next 50 years due to the increased prevalence of risk factors including hypertension, obesity, diastolic dysfunction, inflammation, diabetes and sleep apnea.(2)

Study Results

The study, referred to as the atrial arrhythmia conversion trial or ACT I, was a prospective, randomized, double-blind, placebo-controlled trial of patients with symptomatic AF or nontypical atrial flutter, conducted at 44 sites in Canada, the United States, Denmark, and Sweden. This study assessed the efficacy and safety of vernakalant in converting AF lasting 3 h to <45 d to SR. The current findings are based on a sub-analysis in patients with acute AF lasting 3 to 48 h.

A total of 161 of 356 patients (45 percent) in ACT I presented within 48 hours of AF onset. Of these, 102 patients (63 percent) received vernakalant and 59 patients (37 percent) received placebo.

Patients with AF were randomly assigned in a 2:1 ratio to vernakalant 3 mg/kg or placebo i
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
3. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
4. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
5. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
6. Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
7. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
8. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
9. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
10. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
11. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... MANCHESTER, N.H. , March 2, 2015 ... leading provider of professional-grade vitamins, supplements, prescription ... today announced a strategic partnership with Anabolic ... products for healthcare professionals. This new partnership ... reach into new licensed healthcare practitioner segments ...
(Date:3/2/2015)... Inc. (NYSE MKT: IG), a New Jersey based specialty generic ... and year ended December 31, 2014. Fourth Quarter ... revenues of $13.7 million in the fourth quarter of 2014, ... , Total revenues of $33.7 million for the year ... same period in 2013 , Total net revenues generated ...
(Date:3/2/2015)... Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results ... 2014. Financial highlights for the fourth quarter include revenues of ... $0.04 per share. This compares to revenues of $12.5 million ... share, for the fourth quarter of 2013. Financial highlights for ... a net loss of $68.4 million, or $0.56 per share. ...
Breaking Medicine Technology:Anabolic Laboratories Selects Emerson Ecologics As Distribution Partner 2Anabolic Laboratories Selects Emerson Ecologics As Distribution Partner 3IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 2IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 3IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 4IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 5IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 6IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 7IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 8IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 9IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 10IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 11IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 12Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
... Conference on Avian,Influenza at France's Pasteur Institute, PARIS, ... of,Novavax Inc.'s pandemic influenza vaccine provided protection,against a ... data presented here today at the Second International,Conference ... show that two 0.6 microgram doses of Novavax's,virus-like ...
... of Rare but Devastating,Condition , LONDON, June 1, ... of Leicester and have today (Friday June 1),announced ... rare but,devastating medical condition that can affect children ... clinicians and scientists from the two,universities have already ...
Cached Medicine Technology:Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 2Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 3Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 4World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 2World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 3World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 4World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 5
(Date:3/2/2015)... PA (PRWEB) March 02, 2015 Surgeons ... of the Allegheny Health Network, are exploring ... new software called Visual Info Zonal Reminder (VIZR), to ... Introduced in 2013, Google Glass is a wearable technology ... a smartphone-like hands-free format. Wearers communicate with the Internet ...
(Date:3/2/2015)... UK (PRWEB) March 02, 2015 Market ... research reports worked out by Global Industry Analysts Inc ... Therapy Equipment: Market Research Report . Through 2018, the ... a 6.04% CAGR. The detailed research report suggests a ... for radiation therapy equipment as well as covers the ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 While many ... Title VI of the Civil Rights Act, the unique ... hearing loss are bringing light to the value of ... reveal that nearly 1 in 20 U.S. children have ... 10 in some major cities.(1) Stratus Video Interpreting ...
(Date:3/2/2015)... 02, 2015 Gummy smile reduction ... Gum reshaping can involve one or several procedures to reduce ... gum tissue for a more even gum line. Dr. Farnoosh ... treatment that can permanently lighten discolored or naturally dark ... which involves a personalized treatment plan to address a patient’s ...
(Date:3/2/2015)... York, New York (PRWEB) March 02, 2015 ... Creative Recovery at Recovery Unplugged™—will be delivering a ... A Singer/Songwriter's Perspective on the Art of Healing ... Addiction Disorders (NCAD) and Behavioral Healthcare Executive Summit ... his name, Mr. Supa’s songs have been recorded ...
Breaking Medicine News(10 mins):Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 3Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 2Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 3Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 2Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 3Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 4Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2
... MA Brandeis University selected Jay and Maureen Neitz, the husband-and-wife ... gene therapy to treat vision disorders, as the inaugural recipients ... The award is funded by a $1 million endowment established ... ,75 and Susan K. Feigenbaum ,74, his wife. The endowment ...
... ... is a uniquely designed, extremely resilient, ‘two-in-one’ foam roller. This patented foam roller has ... of the most versatile foam rollers available. , ... Minneapolis, MN (PRWEB) December 17, 2009 -- The SMARTROLLER® ...
... accompanying lung infections , THURSDAY, Dec. 17 (HealthDay News) -- ... flu virus, and researchers say they,ve found a clue as ... illness appears to be a molecule called interleukin 17 (TH17), ... Researchers who analyzed levels of the molecule in swine-flu patients ...
... ... is pleased to announce its newly redesigned Web site: www.psanj.com . PSANJ is a ... as New York magazine and New Jersey Monthly. , ... New Brunswick, NJ (PRWEB) December 17, 2009 -- Plastic Surgery Arts ...
... ... Important ,for the R&D Informatics Industry, , ... Needham, MA (PRWEB) December 17, 2009 -- Cambridge Healthtech Institute ... 2nd Annual Adopting R&D Informatics Systems conference to be held on February 3-5, 2010 ...
... ... Byrne to lead the firm’s Interim Leadership division as senior vice president. A seasoned executive ... B. E. Smith today. , ... Lenexa, KS (Vocus) December 17, 2009 -- B. E. Smith recently hired Deirdre ...
Cached Medicine News:Health News:Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis 2Health News:OPTP Introduces the SMARTROLLER 2Health News:Plastic Surgery Arts of New Jersey (PSANJ) Launches New Web Site 2Health News:Plastic Surgery Arts of New Jersey (PSANJ) Launches New Web Site 3Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 2Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 3Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 3
... Digital Multichannel, with it's streamlined ... of routine laboratory tasks. The ... features: Soft-touch tip ejection, Super ... (0.5-10ul models), Entire pipette autoclavable, ...
... wide variety of applications. • Whole pipette is ... freely rotated against the handle to work in ... angle towards the microtiter plate. • The special ... common pipette tips, and provides a firm, parallel ...
... to operate in a wide variety of applications. ... The manifold can be freely rotated against the ... always at an optimum angle towards the microtiter ... the use of most common pipette tips, and ...
... Features and Benefits: 1-8channel ... a new product number, created ... number. If showing no availability ... old Sigma-Aldrich number (Z37,174-2) or ...
Medicine Products: